Basic Materials · Specialty Chemicals
$1.57
+$0.09+6.44%
Delayed · · marketstack
+$0.02+1.29%over 1M
Price ÷ trailing earnings
Revenue grew −21.93% in FY2025, +25.85% slower than its sector. The median across Basic Materials companies this platform tracks is +3.92%.
No comments yet
Set a username to join the discussion. It’s the only thing shown next to what you post, never your email address.
Comments are written by other users. Nothing here is investment advice and nothing is checked for accuracy.
Updated · the last close
What BGLC has filed with the SEC. This is not BioNexus Gene Lab Corp’s own investor relations site: these filings are the primary source that site publishes from.
Also filed under Specialty Chemicals, ranked by how closely they sit beside BGLC.
The assistant answers from what BGLC has actually filed: 8 annual reports filed with the SEC and 5 Form 4 filings from the last year. Every figure in a reply links to the filing it came from, so an answer can be checked rather than believed.
Press one and the answer appears right here on the page, from BGLC's filings and figures. One a day without an account; a free account has its own, and no card.
See how much of BioNexus Gene Lab Corp each of these investors holds, and every quarter they moved.
Ten seconds. No card. Nothing to cancel.
Be told the moment a BGLC insider trades
Put BioNexus Gene Lab Corp on a watchlist for a free alert, the bell and a daily email, when a Form 4 worth a row is filed, with vesting and automatic tax sales already struck out so what lands is a decision, not paperwork.
The full filing historyMeasure
Ask what growth the price is already betting on
BioNexus Gene Lab Corp's income statement, balance sheet and cash flow as filed, and the ratios computed from them, plus a reverse DCF that holds today's price fixed and solves for the growth it requires.
The reverse DCFMeasure
Watch the same stakes the professionals are watching
Every tracked position priced at the quarter it was filed and diffed against the one before it: how big a bet each one is, and by how much it changed.
Every position, sizedMeasure
Interrogate the filing, not the internet
Ask anything about BioNexus Gene Lab Corp's fundamentals. The assistant answers from its own filings and cites the figure, never a guess from the open web.
Free, no card, and it does not expire.
17 more events are on Measure
Free, no card, and it does not expire. See what the paid plans add
Out of 146 passages in this year’s Item 1A.
New this year
12 more passages are on Bespoke
Free, no card, and it does not expire. See what the paid plans add
From Item 1A of its most recent 10-K, filed April 2026.
And 11 more.
Litigation
MRNA Scientific’s use of “open source” software could subject its proprietary software to general release, adversely affect its ability to sell its tests and subject the company to possible litigation. A portion of the screenings by MRNA Scientific …7 more themes are on Measure
Free, no card, and it does not expire. See what the paid plans add